Beijing Qingyi Taike Pharmaceutical Technology

TsingMed is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of innovative small molecule drugs for metabolic and endocrine disorders. The company leverages a sophisticated structure-based drug design platform to create highly selective therapies aimed at addressing significant unmet medical needs. Its lead candidate, TSM-01, is a selective thyroid hormone receptor beta (THR-β) agonist currently in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Beyond its lead program, TsingMed is advancing a pipeline of multi-target agonists for obesity and type 2 diabetes, as well as early-stage candidates for oncology. Founded by experts with ties to Tsinghua University, the company has secured substantial backing from prominent venture capital firms to accelerate its clinical development programs.